SAAD Centre for Pharmacy and Diabetes, University of Ulster, Coleraine, Northern Ireland, BT52 1SA, UK.
SAAD Centre for Pharmacy and Diabetes, University of Ulster, Coleraine, Northern Ireland, BT52 1SA, UK.
Peptides. 2018 Feb;100:269-274. doi: 10.1016/j.peptides.2017.11.005.
The vast majority of research to date on the gut hormone Peptide YY (PYY) has focused on appetite suppression and body weight regulation effects. These biological actions are believed to occur through interaction of PYY with hypothalamic Y receptors. However, more recent studies have added additional knowledge to understanding of the physiological, and potential therapeutic, roles of PYY beyond obesity alone. Thus, PYY has now been shown to impart improvements in pancreatic beta-cell survival and function, with obvious benefits for diabetes. This effect has been linked mainly to binding and activation of Y receptors by PYY, but more evidence is still required in this regard. Given the potential therapeutic promise of PYY-derived compounds, and complexity of receptor interactions, it is important to fully understand the complete biological action profile of PYY. Therefore, the current review aims to compile, evaluate and summarise current knowledge on PYY, with particular emphasis on obesity and diabetes treatment, and the importance of specific Y receptor interactions for this.
迄今为止,绝大多数关于肠激素肽 YY(PYY)的研究都集中在抑制食欲和调节体重上。这些生物学作用被认为是通过 PYY 与下丘脑 Y 受体的相互作用而产生的。然而,最近的研究增加了对 PYY 除肥胖以外的生理和潜在治疗作用的理解。因此,PYY 现在已被证明可以改善胰腺β细胞的存活和功能,对糖尿病有明显的益处。这种作用主要与 PYY 与 Y 受体的结合和激活有关,但在这方面仍需要更多的证据。鉴于 PYY 衍生化合物的潜在治疗前景以及受体相互作用的复杂性,充分了解 PYY 的完整生物学作用谱非常重要。因此,本综述旨在编译、评估和总结目前关于 PYY 的知识,特别强调肥胖和糖尿病治疗,以及特定 Y 受体相互作用的重要性。